Key Takeaways
- Volume-led recovery, price still absent: Volume jumped 26% this quarter, but margin compression persists because international prices remain subdued after a year of China-led destocking.
- Formulations are doing the heavy lifting: The formulation plant ran above 100% utilization, while the technical plant sat at 66%, reflecting a deliberate shift toward higher-value formulation sales and internal consumption of technical material.
- Backward integration milestone reached: An intermediate plant for a key fungicide was commissioned, a step management frames as both margin-accretive and import-substituting.
- Margins have a floor, not a ceiling: Management expects EBITDA to recover to 18–20% from Q3 onward, but explicitly ruled out a return to the 25%+ peaks of 2021–22 as sustainable.
- What to watch next quarter: Whether the Q3 price recovery materializes as forecast, the pace of Hamirpur technical plant commissioning, and any stabilization in export realizations.
Volume & Revenue Growth
- Volume surge, price drag: Volume grew 26% YoY, driven by higher formulation sales and a gradual pickup in export volumes, while price realization remained under pressure from elevated channel inventory and China destocking.
- Revenue mix shift: Formulation sales showed significant growth; technical sales were steady as exports dipped slightly and more technical material was consumed internally for formulations.
- New molecule contribution: New molecules delivered roughly ₹40 crores in revenue, about 18–19% of the quarter's topline, reflecting a pipeline that is beginning to convert.
- July momentum: Management noted July has been very good year-on-year, including for herbicides, suggesting the domestic Kharif season is providing a tailwind.
- FY25 growth is a volume bet: The 15–20% revenue growth projection for FY25 is mostly volume-led; management conceded that a price increase of 3–4% by Q3 or Q4 would push growth above that range, but price visibility remains low.
S.P. Gupta: "Our volume has increased by 26% this quarter."
Margins: The Price-Led Squeeze
- Price, not cost, is the culprit: Margin decline was mostly price-led, driven by higher channel inventory in international markets and adverse weather, which pushed global agrochemical prices down significantly.
- The 25% era is over: Management was explicit that margins exceeding 25%, achieved in 2021 and 2022, are being rationalized and cannot be sustainable given the capacity built worldwide and current demand patterns.
- Cost-side pressures: Employee expenses rose due to a deliberate decision to strengthen R&D and expand the foundation marketing team; freight charges also increased significantly because of Red Sea logistical challenges.
- Recovery path: Management expects price recovery from Q3 onward, targeting 18–20% EBITDA margin from that point, but declined to give full-year EBITDA guidance, calling it difficult.
- 22–23% is aspirational, not promised: When asked if a substantial price increase in FY26 could lift margins to 22–23%, management said it would like to if opportunity arises, but noted the overall market remains subdued and big price increases are difficult.
S.P. Gupta: "Those margins were achieved in 2021 and 2022, they are being rationalized. The margins exceeding 25% cannot be sustainable seeing the current situation."
Capacity & Operations
- Utilization split: Technical plant operated at 66%, while the formulation plant ran above 100%, achieved by using some technical facilities to meet formulation demand. Combined utilization was roughly 80%.
- Formulation capacity expanding: Increased formulation capacity will be commissioned within this month or next month, addressing the bottleneck that forced the company to repurpose technical assets.
- Hamirpur progress: The formulation plant was commissioned on a small scale in March; technical plants are still under construction and expected to be commissioned in the last quarter of this financial year. Two molecules have been zeroed down for the site, with work ongoing.
- Inventory normalization: Inventory days declined significantly compared to FY24, as the earlier buildup was driven by a sharp export turnover decline in Q3 and Q4 of last year, not by an increase in absolute inventory.
- Growth headroom exists: Management stated the technical plant has enough capacity and, with the formulation expansion, there is sufficient capacity for further growth without immediate large-scale capex.
D.K. Jain: "Our present capacity utilization is 66% of technical and more than 100% of formulation. If we combine together the overall capacity, it is almost about 80%."
Export & Domestic Demand
- Export volumes turning, prices lagging: Export volumes have started picking up gradually, but prices have settled at a lower level and recovery remains soft. Management expects overall export volume improvement in coming quarters.
- China destocking may be ending: Prices of technical products have been reducing continuously over the last year due to China destocking; management indicated distribution from China may be getting over, which could support price stabilization.
- Domestic market recovering: Signs of recovery are visible in the domestic market, primarily driven by good sowing in the Kharif season. The company expects domestic market growth of 8–10% annually, aided by recently introduced domestic-oriented products.
- Export decline explained: The reduction in exports was attributed to higher channel inventory and adverse weather in some geographies, not structural demand destruction.
S.P. Gupta: "It will be definitely far better than FY24 numbers. Second half will be far better. Since last year export has declined very, very sharply. So now we are seeing in the international market, volumes are picking up."
Strategic Initiatives
- Backward integration milestone: The company commissioned an intermediate plant, a significant step toward backward integration of a key fungicide that was previously largely imported. Management framed this as enhancing self-reliance and contributing to domestic economic growth.
- Pipeline additions: One intermediate already added; one more intermediate capacity increase is planned, plus two more active ingredients will be added this year, broadening the product portfolio.
- Hamirpur molecule strategy: Of the two molecules zeroed down for Hamirpur, one does not need registration as it falls outside the insecticides category; registration for the other was submitted long back and is expected by next month.
- R&D and marketing investment: The deliberate rise in employee expenses reflects a bet on strengthening R&D capabilities and expanding the foundation marketing team, positioning for the next growth phase even as margins are compressed.
Anand Swarup Agarwal: "By substituting imports with domestic manufacturing, we are not only enhancing our self-reliance but also contributing to the nation's economic growth."
Balance Sheet & Capital Allocation
- Capex plan: The company aims to spend ₹110 crores in FY25, combining both India Pesticides and its subsidiary Shalvis Specialties, funded entirely from internal accruals.
- Cash surplus position: Management stated the company will remain cash surplus even after the capex program for the next 1–2 years, implying no near-term dilution or debt risk.
- Subsidiary contribution minimal: Shalvis Specialties operations are stabilizing but will largely not contribute much to revenue this year, keeping the consolidated story dependent on the parent.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 15–20% YoY, mostly volume-led; above that if 3–4% price increase materializes | FY25 |
| EBITDA margin recovery | 18–20% from Q3 onward | Q3 FY25 onward |
| Capex | ₹110 crores, funded from internal accruals | FY25 |
| Hamirpur technical plant commissioning | Two molecules; plants expected to commission | Last quarter FY25 |
| Formulation capacity expansion | Increased capacity commissioned | Within this month or next month |
| Revenue growth (FY26) | 15–20% YoY | FY26 |
| EBITDA margin (FY26) | 18–20% | FY26 |
| Cash position | Remain cash surplus | Next 1–2 years |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Revenue | ₹224 cr, +9% YoY and +72% QoQ |
| EBITDA | ₹32 cr, 15% margin vs 13% in Q1 FY24 |
| EBITDA margin | 14.2%, improved 149 bps YoY and 854 bps QoQ |
| Net profit | ₹19 cr, +25% YoY |
| Domestic revenue | ₹143 cr |
| International revenue | ₹77 cr |
| Technical sales | ₹142 cr vs ₹158 cr in Q1 FY24 |
| Formulation sales | ₹78 cr vs ₹43 cr in Q1 FY24 |
| Volume growth | 26% YoY |
| Revenue from new molecules | ~₹40 cr, 18-19% of revenue |
| Technical capacity utilization | 66% |
| Formulation capacity utilization | >100%, using some technical facilities |
| Overall capacity utilization | ~80% |
| FY25 capex plan | ₹110 cr, combining IPL (₹50 cr) and SSL (₹65 cr) |
| Cash in hand | ₹140 cr |